title: Cancer and the potential place for growth hormone receptor antagonist therapy.
abstract: Pegvisomant is a recombinant protein, structurally similar to natural human growth hormone (GH), which is capable of binding to the GH receptor as a competitive antagonist. As well as being evaluated for the treatment of acromegaly, pegvisomant is being investigated as a possible antineoplastic agent, initially in mice. So far, in vitro efficacy against meningioma and in vivo efficacy against colon and breast cancer cell lines have been examined.
authors.affiliation: MD Anderson Cancer Center, University of Texas, Houston, USA. Keith.Friend@am.pnu.com
authors.forename: K E
authors.initials: KE
authors.lastname: Friend
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000378:metabolism; D019382:Human Growth Hormone / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008579:Meningioma / Q000188:drug therapy; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors*; D014407:Tumor Cells, Cultured
chemical_list: D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; C406545:pegvisomant